Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...

Just two days after starting at the FDA, the agency’s Chief Counsel Hilary Perkins is signing off, effective immediately. | ...

Following a fire at a Bayer executive’s New Jersey home earlier this month, at least eight agencies—including the Federal ...

In a year in which he faced down a challenge from an activist investor, Pfizer CEO Albert Bourla, Ph.D., received a 14% total ...

AstraZeneca has been urging sports fans to “Get Body Checked Against Cancer” in a campaign launched in collaboration with the ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

The U.K. government is proposing to raise the rebate rate under a national drug cost program, drawing complaints from the ...

Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia ...

In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...

Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...

Based on internal projections for demand, the two companies have approved about $150 million in additional investments to ...

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...